A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Hyperlipidemia, sponsored by Pfizer. Completed at 59 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-11-16.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing atorvastatin in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Atorvastatin · Hyperlipidemias.
Among the 37 studies testing atorvastatin in Hyperlipidemias, this one is the 4th largest by enrollment, is one of 3 that started in 2004, is one of 10 in phase 3, and was the 6th registered.
862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.
Browse Hyperlipidemias studies →None of the 37 studies testing atorvastatin in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 11 · Phase 4 10
First in 1998; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 900 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 99 across the 37 interventional studies. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 37 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
27 studies in Hyperlipidemias by Pfizer: none open now, none under way, none of them phase 3. Of 26 finished, 9 (35%) have results posted.
Among the 27 studies in Hyperlipidemias by Pfizer, this one is the 7th largest by enrollment, is one of 2 that started in 2004, is one of 17 in phase 3, and was the 4th registered.
Pfizer’s Hyperlipidemias studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 37 studies testing atorvastatin in Hyperlipidemias, from their registry updates:
Among Pfizer’s 27 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias
For additional information please call: 1-800-718-1021
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug pages: Torcetrapib · Atorvastatin
Change in lipid parameters (HDL, LDL) at various timepoints over 12 months.
Changes in levels of lipids and other biomarkers.
The record gives a start of Nov 2004 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Torcetrapib · Atorvastatin